Cargando…

Clinical Considerations During Breakthrough Coronavirus Disease 2019 Infections in Vaccinated Individuals With Autoimmunity

Detalles Bibliográficos
Autores principales:	Rocco, Joseph M, Pei, Luxin, Galindo, Frances, Laidlaw, Elizabeth, Sereti, Irini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669033/ https://www.ncbi.nlm.nih.gov/pubmed/34917696 http://dx.doi.org/10.1093/ofid/ofab577

Ejemplares similares

Trismus and voice change after starting tuberculosis treatment
por: Rocco, Joseph M., et al.
Publicado: (2021)

Plasma Metabolomics Reveals Dysregulated Metabolic Signatures in HIV-Associated Immune Reconstitution Inflammatory Syndrome
por: Pei, Luxin, et al.
Publicado: (2021)

Booster vaccines for COVID-19 vaccine breakthrough cases?
por: Nixon, Douglas F, et al.
Publicado: (2022)

Breakthrough infections in MPN-COVID vaccinated patients
por: Barbui, Tiziano, et al.
Publicado: (2022)

Split-dosing of coronavirus disease 2019 vaccines
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

1381. M.genavense in the ART Era: From Persistent Disseminated Disease to Severe Disease
por: Manion, Maura, et al.
Publicado: (2019)

Considerations on SARS-CoV-2 vaccines in patients with autoimmune blistering diseases
por: Cozzani, Emanuele, et al.
Publicado: (2021)

Letter to the Editor: Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use
por: Ng, Alexander Clevewood
Publicado: (2021)

Booster vaccines for COVID-19 vaccine breakthrough cases? – Authors' reply
por: Krause, Philip R, et al.
Publicado: (2022)

Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients
por: Lage, Silvia Lucena, et al.
Publicado: (2022)

Letter to the Editor: Reply to Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use
por: Efe, Cumali, et al.
Publicado: (2021)

Immune response after vaccination using inactivated vaccine for coronavirus disease 2019
por: Sun, Ya, et al.
Publicado: (2023)

Aseptic Meningitis and mRNA Coronavirus Disease 2019 Vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Hyperinflammatory Syndromes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA vaccination in Individuals With Underlying Immune Dysregulation
por: Rocco, Joseph M, et al.
Publicado: (2021)

Breakthrough SARS-CoV-2 Infections in Prison after Vaccination
por: Brinkley-Rubinstein, Lauren, et al.
Publicado: (2021)

Mandatory vaccination in child daycare and its relevance to coronavirus disease 2019
por: den Exter, André
Publicado: (2021)

Reply: Aseptic Meningitis and mRNA Coronavirus Disease 2019 Vaccine
por: Heo, Sang Taek
Publicado: (2022)

Coronavirus disease 2019 vaccines: challenges of using global mass vaccination to achieve herd immunity
por: Bao, Pengtao, et al.
Publicado: (2023)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Coronavirus disease 2019 vaccine for children in China: when to start? Mandatory or voluntary?
por: Liu, Fei, et al.
Publicado: (2021)

Coronavirus disease 2019 (COVID‐19) vaccination in patients with cirrhosis: Does it work?
por: Calleri, Alberto, et al.
Publicado: (2022)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis
por: Parikh, Sameer A., et al.
Publicado: (2022)

Post-Vaccination Coronavirus Disease 2019: A Case-Control Study and Genomic Analysis of 119 Breakthrough Infections in Partially Vaccinated Individuals( )
por: Baltas, Ioannis, et al.
Publicado: (2021)

Famotidine and Coronavirus Disease 2019
por: Freedberg, Daniel E., et al.
Publicado: (2021)

Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential
por: Khoury, Maroun, et al.
Publicado: (2020)

Novel breakthrough in the treatment of sphingomyelinase deficiency
por: Sultan, Wania, et al.
Publicado: (2023)

Breakthrough cases of COVID-19 in vaccinated United States Veterans with spinal cord injuries and disorders
por: Sankary, Kendl M., et al.
Publicado: (2021)

Immune parameters during anaphylaxis to messenger RNA coronavirus disease 2019 vaccines: Not the usual suspects?
por: de Chaisemartin, Luc, et al.
Publicado: (2022)

Antibody response to coronavirus disease 2019 vaccines after allergic reaction to first dose: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Updates on the coronavirus disease 2019 vaccine and consideration in children
por: Kang, Hyun Mi, et al.
Publicado: (2021)

Famotidine and Mortality in Coronavirus Disease 2019
por: Sethia, Rahul, et al.
Publicado: (2021)

Asthma and prognosis of coronavirus disease 2019
por: Özdemir, Öner
Publicado: (2022)

Individualizing dialysis dose under certain circumstances during the Severe Acute Respiratory Syndrome Coronavirus-2 (coronavirus disease 2019) pandemic: a perspective
por: Abdelaziz, Tarek Samy
Publicado: (2020)

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
por: Kuhlmann, Constanze, et al.
Publicado: (2022)

Vaccine breakthrough infections in veterans hospitalized with coronavirus infectious disease-2019: A case series
por: Kim, Paul S., et al.
Publicado: (2022)

Improvement of liver metabolic activity in people with advanced HIV after antiretroviral therapy initiation
por: Patel, Reema, et al.
Publicado: (2022)

MicroCLOTS pathophysiology in coronavirus disease 2019
por: Renzi, Samuele, et al.
Publicado: (2023)

Impact of coronavirus disease 2019 on the clinical diagnosis and treatment of breast cancer in China
por: Si, Yi-Ran, et al.
Publicado: (2021)

Antibody Response to the Coronavirus Disease 2019 Ad26.COV2.S Vaccine Among Maintenance Dialysis Patients
por: Ficociello, Linda H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6a3j7pqojcce2pp8gebo1prdus